Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galcanezumab in Mild-to-Moderate Alzheimer's Disease
NCT07323927Phase 1Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Aug 2025
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of galcanezumab in Alzheimer's disease (AD), sponsored by Xuanwu Hospital. Primary endpoint: Calcitonin Gene-Related Peptide Levels in Cerebrospinal Fluid and Plasma at 24 weeks. Started Aug 2025; status: recruiting.
02
Drugs
galcanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07323927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07323927.